373 related articles for article (PubMed ID: 29530797)
1. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Cho YY; Cho SI
Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
Ha KH; Kim B; Choi H; Kim DJ; Kim HC
Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
4. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
6. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
[TBL] [Abstract][Full Text] [Related]
7. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
8. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
9. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
10. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
11. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
[TBL] [Abstract][Full Text] [Related]
12. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
[TBL] [Abstract][Full Text] [Related]
13. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
Wang J; Wu HY; Chien KL
Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
[TBL] [Abstract][Full Text] [Related]
15. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
16. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.
Park SH; Choi YJ; Rhee EJ; Huh KB
Endocrinol Metab (Seoul); 2019 Mar; 34(1):70-79. PubMed ID: 30912340
[TBL] [Abstract][Full Text] [Related]
19. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]